Nebenwirkungen · Vaxneuvance
Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 7
HOS-147689 · Präparat HOS-099718
The most frequent adverse reactions are injection-site pain (65%), fatigue (23 %), myalgia (21%), headache (17%), injection-site swelling (16%), injection-site erythema (11%) and arthralgia (8%). The majority of adverse reactions were mild (based on intensity or size) and of short duration (≤3 days); severe reactions (defined as an event that prevents normal daily activity or size of injection-site reaction >10 cm) occurred in ≤2% of adults across the clinical program.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-16T14:19:00Z · SHA-256 8c806efad2c6480965326c02c35aa390b1a5f1070feca6a9495a17a403d294b7 · Passage 8de372b041ebe2f065ae591ac311bb2f8fbf853cd7949698c8829ee606496234 · Zeichen 2716–3189 im Abschnitt